XTX Topco Ltd Takes Position in Bicycle Therapeutics plc (NASDAQ:BCYC)

XTX Topco Ltd purchased a new position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,177 shares of the company’s stock, valued at approximately $206,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. increased its stake in Bicycle Therapeutics by 71.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,859 shares of the company’s stock worth $171,000 after buying an additional 2,858 shares in the last quarter. PNC Financial Services Group Inc. acquired a new position in Bicycle Therapeutics in the 4th quarter valued at $137,000. PDS Planning Inc purchased a new position in Bicycle Therapeutics in the 1st quarter valued at $210,000. Natixis Advisors LLC acquired a new stake in Bicycle Therapeutics during the 2nd quarter worth $261,000. Finally, Concurrent Investment Advisors LLC purchased a new stake in shares of Bicycle Therapeutics during the first quarter worth $543,000. 86.15% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on BCYC shares. B. Riley downgraded shares of Bicycle Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $33.00 to $28.00 in a research note on Wednesday, August 7th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 target price on shares of Bicycle Therapeutics in a research note on Monday, September 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. JMP Securities reiterated a “market outperform” rating and set a $32.00 price objective on shares of Bicycle Therapeutics in a research report on Monday, September 16th. Finally, Royal Bank of Canada started coverage on Bicycle Therapeutics in a report on Friday, September 6th. They issued an “outperform” rating and a $35.00 target price for the company. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.56.

Insider Buying and Selling at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 3,194 shares of the firm’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $19.64, for a total transaction of $62,730.16. Following the completion of the transaction, the chief executive officer now directly owns 384,076 shares in the company, valued at $7,543,252.64. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold a total of 4,555 shares of company stock valued at $89,460 over the last quarter. 8.50% of the stock is owned by company insiders.

Bicycle Therapeutics Stock Down 0.5 %

Shares of NASDAQ:BCYC opened at $23.21 on Monday. The company has a market capitalization of $992.90 million, a price-to-earnings ratio of -5.22 and a beta of 0.90. Bicycle Therapeutics plc has a 12-month low of $12.54 and a 12-month high of $28.20. The business has a 50-day moving average price of $23.49 and a 200 day moving average price of $22.95. The company has a current ratio of 14.77, a quick ratio of 14.77 and a debt-to-equity ratio of 0.01.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.33. The business had revenue of $9.36 million for the quarter, compared to the consensus estimate of $6.13 million. Bicycle Therapeutics had a negative net margin of 417.88% and a negative return on equity of 32.80%. Bicycle Therapeutics’s revenue for the quarter was down 17.9% compared to the same quarter last year. Sell-side analysts expect that Bicycle Therapeutics plc will post -3.17 EPS for the current year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.